Logo Logo Logo Logo Logo
SOLY News

Soliton Files Special 510(k) with FDA for its Generation II RAP Device

February 11, 2020
SOLY News

Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device

December 18, 2019
SOLY News

Soliton To Announce Keloid and Hypertrophic Scar Clinical Trial Data on October 24, 2019

October 8, 2019
SOLY News

Soliton Announces Site Selected for Clinical Trial to Treat Fibrotic Scars

September 10, 2019
Featured News SOLY News Top News

Soliton Announces Positive Results Demonstrated from Longer RAP Treatment

August 20, 2019
SOLY News

Soliton Treats First Patients in Pivotal Cellulite Trial

August 14, 2019
SOLY News

Soliton Announces Patient Recruitment Has Begun for Pivotal Cellulite Trial

August 12, 2019
SOLY News

Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite

June 4, 2019
SOLY News

Soliton to Initiate Pivotal Cellulite Trial after Positive Proof-of-Concept Trial Results with 20-47% Improvement in Cellulite Severity Score

May 29, 2019
Featured News SOLY News

Soliton Receives FDA 510(k) Clearance of its Acoustic Shockwave RAP Device

May 28, 2019
  • 1
  • 2
  • 3
Hottest Stuff Now
Sorry, no posts matched your criteria.
FOLLOW US #QODETHEMES
QodeThemes
It seams that you haven't connected with your Twitter account
INSTAGRAM FEED
Sign Up & Get FREE News Alerts From FNM Today!
Sign Up

Terms of Service | Privacy Policy | Disclaimer

FinancialNewsMedia.com (FNM) is a third party publisher and news dissemination solutions provider of multimedia platforms that enable officers & directors, corporate communicators, public relations and investor relations officers to leverage content to engage with all their key audiences. Any ideas and opinions presented in any FNM News Alerts, Video clips, Press Releases, RSS Feeds or Social Network Posts are for informational purposes only, and do not reflect the opinions of FNM or any of its affiliates, subsidiaries or partners. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT CONTAINED HEREIN BE INTERPRETED TO REPRESENT TRADING OR INVESTMENT ADVICE. All viewers agree that under no circumstances will FNM, its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information contained on this or any affiliated website.
© 2020 Financial News Media. All Rights Reserved.